

ImmuneOnco (1541.HK)

Promising results of IMM01 released at ASCO

ImmuneOnco is a clinical-stage biotech company focusing on innate immune systems. It has built a differentiated CD47-based portfolio with favourable safety and efficacy profiles. The Company has a rich pipeline with 8 drug candidates in clinical studies. The key product asset Timdarpcept (IMM01), a SIRPα-Fc Fusion protein targeting CD47, has moved to Ph3 studies, with three clinical-stage CD47-based bispecific molecules in clinical studies, including MM0306 (CD47×CD20), IMM2902 (CD47×HER2) and IMM2520 (CD47×PD-L1). Additionally, IMM2510 (VEGF x PD-L1) and IMM27M (CTLA-4 ADCC+) are also being investigated in clinical studies. At 2024 ASCO meeting, ImmuneOnco had two oral presentations for IMM01, including 1) the latest Ph2 results of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS, [link](#)), and 2) the latest Ph2 results of IMM01 in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma (cHL, [link](#)).

- **Robust response of IMM01+AZA for 1L high-risk MDS.** Among the 51 efficacy evaluable MDS patients, IMM01+AZA demonstrated an ORR of 64.7%, including 33.3% CR, 15.7% mCR with hematologic improvement, 11.8% mCR and 3.9% HI alone. Among the 34 efficacy evaluable patients who received initial treatment ≥ 4 months, ORR increased to 85.3%, with 50.0% CR rate. For the 29 efficacy evaluable patients who received initial treatment ≥ 6 months, ORR further improved to 89.7%, with 58.6% CR rate. The median time to response was 1.9 months and the median DoR was not reached. 12-month OS rate was 71.1%. IMM01+AZA combination treatment led to significant recoveries of HGB and PLT, as well as the significant reduction in RBC or PLT transfusions. In terms of safety, in this Ph2 trial, TRAEs leading to treatment discontinuation occurred in 3 patients (5.3%) and only 1 patient had Grade 3 hemolysis reported but resolved after treatment.
- **Strong efficacy signals of IMM01+tislelizumab in anti-PD-1 failed cHL.** In 33 efficacy evaluable anti-PD-1 failed cHL patients (n=33), with a median follow-up of 6.87 months, IMM01+tislelizumab achieved ORR of 66.7% (22/33) with 24.2% (8/33) CR. 87.9% (29/33) of patients had target lesion size reduction. mPFS and mDOR were not reached. IMM01+tislelizumab also demonstrated a tolerated safety profile for cHL, with most of the TRAEs being grade 1-2 hematologic toxicities. The most common 3-4 TRAEs included WBC decreased (12.1%), PLT decreased (12.1%), ANC decreased (12.1%) and anemia (6.1%), which were full recovery or recovery to grade 1/baseline level after symptomatic treatment. There was no hemolysis event reported, and no patients experienced TRAEs leading to the study drug discontinuation or death.
- **Ph3 studies on the way for further validation.** The promising efficacy and well-tolerated safety profile observed in the Ph2 trials of IMM01 warrants the initiation of Ph3 studies to further validate its potential. IMM01 has recently received approvals from CDE to conduct Ph3 clinical trials in 1L high-risk MDS (+AZA), PD-1-failed cHL (+tislelizumab), as well as in combination with AZA for the first-line chronic myelomonocytic leukemia (CMML). We expect the Company to file a BLA for IMM01 for treatment of cHL in 2026, with potential to become the first CD47 targeted therapy in China.

Earnings Summary

(YE 31 Dec) (RMB mn)	FY21A	FY22A	FY23A
Revenue	5	1	0
R&D expenses	(176)	(277)	(292)
Admin expenses	(48)	(93)	(80)
Net profit/loss	(733)	(403)	(379)
Year-end cash balance	676	635	609

Source: Company data

NOT RATED

Current Price **HK\$14.44**

China Healthcare

Jill Wu, CFA
(852) 3900 0842
jillwu@cmbi.com.hk

Andy Wang
(852) 3657 6288
andywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$m)	5,403
Avg 3-mths t/o (HK\$m)	4.04
52w High/Low (HK\$)	32.15/13.58
Total Issued Shares (mn)	229

Source: FactSet

Shareholding Structure

Tian Wenzhi	15.35%
Halo Biomedical Investment	7.88%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	4.3%	4.6%
3-mth	-2.5%	-14.5%
6-mth	-52.2%	-57.6%

Source: FactSet

12-mth Price Performance



Source: FactSet

Website: <http://cn.immuneonco.com/>

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.